Laurence Harris

A transatlantic Cooley team successfully represented biopharmaceutical company IQVIA in a breach of contract and unfair business practices case in which the High Court of Justice of England and Wales rendered a lengthy and detailed verdict in favor of IQVIA on all claims and counterclaims. Partners Mike Klisch, Henry Stewart, Laurence Harris and Bob Cahill led the Cooley team advising IQVIA.

Cooley advised Bavarian Nordic, an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases, on its agreement to acquire the manufacturing and global rights to two commercial vaccines – Rabipur/RabAvert and Encepur – from GlaxoSmithKline, for €796 million. Partners Nicola Maguire and John Wilkinson led the Cooley team.

Advising a US public company on a dispute arising out of the termination of an international licensing and collaboration agreement of the development of a drug including a Phase 2 trial. The case involved obtaining a mandatory injunction in support of arbitration proceedings and obtaining a substantial judgment and damages for the client.